Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of Lu AF35700 in adults with treatment-resistant schizophrenia
2015-003284-11Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lu af35700 in schizophrenia, sponsored by Lundbeck. Primary endpoint: Safety and tolerability of long-term Lu AF35700 treatment. Started Jul 2016; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2015-003284-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003284-11.